King & Wood Mallesons’ cross-border team advised UK-based Vaccitech, a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world, in its collaboration with China-based CanSino Biologics, to develop a new vaccine approach to prevent shingles (herpes zoster).

KWM’s cross border-team was led by corporate partner Barri Mendelsohn (London) together with Life Sciences and IP specialist, Anna Feros, and a team in China led by partner and head of KWM’s China healthcare group Huang Jianwen.

London-based corporate partner, Barri Mendelsohn comments: “We are delighted to work with Vaccitech on its collaboration with China-based CanSino Biologics on this significant vaccine, and to leverage our global corporate and life sciences expertise.” Barri adds: “We are seeing an upturn in innovative UK-focused deals as well as UK-China collaborations, including notably advising Luye Pharma on its US$546 million acquisition and licence of the rights to Seroquel and Seroquel XR (Products) in 51 international markets from AstraZeneca.”